Department of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Institute of Refractory Thyroid Cancer, Yonsei University College of Medicine, Seoul, Republic of Korea.
Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Front Endocrinol (Lausanne). 2023 Feb 9;14:1064050. doi: 10.3389/fendo.2023.1064050. eCollection 2023.
Primary thyroid lymphoma (PTL) is a very rare entity accounting for 5% of all thyroid malignancies and less than 2% of lymphomas. PTLs are classified as non-Hodgkin's B-cell lymphomas in the majority of cases, although Hodgkin's lymphoma of the thyroid has also been identified. This study aimed to identify the clinical, biochemical, and pathological features of primary thyroid lymphomas.
From January 2008 to December 2020, data from patients diagnosed with PTL treated at the Gangnam Severance Hospital, including clinical, biochemical, and pathological features of thyroid lymphomas, were assessed.
Of 10 patients, nine women and one man, with a median age of 62 (range, 44-82) years were included. Fine needle aspiration biopsy was performed in nine patients and surgical resection was performed in one patient without biopsy. Excisional and surgical biopsies were performed in all patients, including five who underwent excisional biopsy and five who underwent thyroidectomy. Histological analyses revealed that all 10 lymphomas were non-Hodgkin B-cell lymphoma; six patients had diffuse large B-cell lymphoma, three had mucosa-associated lymphoid tissue lymphoma, and one had Burkitt lymphoma. Four patients received chemotherapy, two were treated with chemoradiation therapy, one received radiation therapy only, one did not require more treatment after surgery, one refused treatment, and one was transferred to another hospital.
Although PTLs are scarce, clinicians should be aware of this rare entity and evaluate and treat PTLs on an individual basis.
原发性甲状腺淋巴瘤（PTL）是一种非常罕见的疾病，占所有甲状腺恶性肿瘤的 5%，不到淋巴瘤的 2%。在大多数情况下，PTL 被归类为非霍奇金 B 细胞淋巴瘤，尽管也已确定有甲状腺霍奇金淋巴瘤。本研究旨在确定原发性甲状腺淋巴瘤的临床、生化和病理特征。
从 2008 年 1 月至 2020 年 12 月，评估了在江南塞弗伦斯医院治疗的 PTL 患者的临床、生化和病理特征等数据。
纳入了 10 名患者，其中 9 名女性和 1 名男性，中位年龄为 62 岁（范围 44-82 岁）。9 名患者进行了细针穿刺活检，1 名患者未进行活检即进行了手术切除。所有患者均进行了切除性和手术活检，其中 5 名患者进行了切除活检，5 名患者进行了甲状腺切除术。组织学分析显示，所有 10 例淋巴瘤均为非霍奇金 B 细胞淋巴瘤；6 例为弥漫性大 B 细胞淋巴瘤，3 例为黏膜相关淋巴组织淋巴瘤，1 例为伯基特淋巴瘤。4 名患者接受了化疗，2 名患者接受了放化疗，1 名患者仅接受了放疗，1 名患者在手术后无需进一步治疗，1 名患者拒绝治疗，1 名患者转院。
尽管 PTL 较为罕见，但临床医生应意识到这种罕见疾病，并根据个体情况评估和治疗 PTL。
